BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Treiber G, Wex T, Schleyer E, Troeger U, Hosius C, Malfertheiner P. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function. Cancer Lett. 2008;260:146-154. [PMID: 18083304 DOI: 10.1016/j.canlet.2007.10.041] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Oseini AM, Roberts LR. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009;13:443-54. [PMID: 19335066 DOI: 10.1517/14728220902719233] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
2 Lee C, Chao Y, Chang S, Chen W, Hung K, Liu S, Juang J, Chen Y, Wang F. Nanofibrous rhPDGF-eluting PLGA–collagen hybrid scaffolds enhance healing of diabetic wounds. RSC Adv 2016;6:6276-84. [DOI: 10.1039/c5ra21693a] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
3 Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf  J, Jaehde U. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles. Clinical Pharmacokinetics 2011;50:551-603. [DOI: 10.2165/11593320-000000000-00000] [Cited by in Crossref: 132] [Cited by in F6Publishing: 107] [Article Influence: 13.2] [Reference Citation Analysis]
4 Schiavon G, Eechoute K, Mathijssen RHJ, de Bruijn P, van der Bol JM, Verweij J, Sleijfer S, Loos WJ. Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction. The Journal of Clinical Pharmacology 2012;52:1115-20. [DOI: 10.1177/0091270011409235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
6 Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol 2009;135:271-81. [PMID: 18642029 DOI: 10.1007/s00432-008-0443-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
7 van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692-706. [PMID: 19733976 DOI: 10.1016/j.ctrv.2009.08.004] [Cited by in Crossref: 272] [Cited by in F6Publishing: 222] [Article Influence: 22.7] [Reference Citation Analysis]
8 Mizuguchi Y, Takizawa T, Uchida E. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015;7:696-702. [PMID: 25866606 DOI: 10.4254/wjh.v7.i4.696] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
9 Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-204. [PMID: 19120703 DOI: 10.1111/j.1582-4934.2008.00533.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 15.2] [Reference Citation Analysis]
10 de Wit D, Guchelaar H, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discovery Today 2015;20:18-36. [DOI: 10.1016/j.drudis.2014.09.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
11 Motawi TM, Sadik NA, Fahim SA, Shouman SA. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact 2015;233:147-56. [PMID: 25863232 DOI: 10.1016/j.cbi.2015.03.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
12 Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev 2013;65:578-640. [PMID: 23406671 DOI: 10.1124/pr.111.005439] [Cited by in Crossref: 86] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
13 Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Crit Rev Oncol Hematol 2019;141:112-24. [PMID: 31276964 DOI: 10.1016/j.critrevonc.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
15 Kassem MA, El-sawy HS, Abd-allah FI, Abdelghany TM, El-say KM. Maximizing the Therapeutic Efficacy of Imatinib Mesylate–Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design. Journal of Pharmaceutical Sciences 2017;106:111-22. [DOI: 10.1016/j.xphs.2016.07.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
16 Beumer JH, Pillai VC, Parise RA, Christner SM, Kiesel BF, Rudek MA, Venkataramanan R. Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. Br J Clin Pharmacol 2015;80:1097-108. [PMID: 26178713 DOI: 10.1111/bcp.12723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]